CompanyGraph
Suzhou Novoprotein Scientific Co., Ltd.
688137 · SSE · China
novoprotein.com.cnFinancials as of FY2025
What stands out
- Valued far above the size of its business
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $22.91M, lower than 95% of all stocks globally
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
7.48BCNY1.12B · vs all stocks (USD)
Revenue (TTM)
152.84MCNY22.91M · vs all stocks (USD)
Profit Margin
-54.15%vs Biotechnology peers
Beta
1.27xvs all stocks
52-Week Change
153.25%vs all stocks
Market Capitalization
7.48BCNY1.12B · vs all stocks (USD)
Enterprise Value
5.83BCNY874.39M · vs all stocks (USD)
Price to Sales (TTM)
48.95xvs Biotechnology peers
Price to Book (MRQ)
3.72xvs Biotechnology peers
Enterprise to Revenue
38.17xvs Biotechnology peers
Enterprise to EBITDA
-80.29xvs Biotechnology peers
Gross Margin
67.36%vs Biotechnology peers
Profit Margin
-54.15%vs Biotechnology peers
Operating Margin
-66.84%vs Biotechnology peers
Return on Assets (TTM)
-2.51%vs Biotechnology peers
Return on Equity (TTM)
-4.06%vs Biotechnology peers
Revenue (TTM)
152.84MCNY22.91M · vs all stocks (USD)
Revenue per Share (TTM)
2.18CNYUpdated Oct 24, 2026Quarterly Revenue Growth
6.70%vs Biotechnology peers
Gross Profit (TTM)
84.79MCNY12.71M · vs all stocks (USD)
EBITDA (TTM)
-72.67MCNY-10.89M · vs all stocks (USD)
Net Income (TTM)
-82.76MCNY-12.40M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
23.34%vs Biotechnology peers
Operating Cash Flow (TTM)
-22.03MCNY-3.30M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-72.68MCNY-10.89M · vs all stocks (USD)
Payout Ratio
277.78%vs Biotechnology peers
Revenue
146.44MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
48.15MCNYFY2025 · Dec 31, 2025Gross Profit
98.29MCNYFY2025 · Dec 31, 2025Operating Income
-66.69MCNY-9.99M · vs all stocks (USD)
Pre-tax Income
-70.37MCNYFY2025 · Dec 31, 2025Income Tax Expense
7.41MCNYFY2025 · Dec 31, 2025Net Income
-77.78MCNYFY2025 · Dec 31, 2025EBIT
-67.83MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-6.71MCNYFY2025 · Dec 31, 2025Research & Development
64.06MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
33.64MCNYFY2025 · Dec 31, 2025Other Operating Expenses
1.50MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
31.73MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
2.54MCNYFY2025 · Dec 31, 2025EPS (Basic)
-1.11CNYFY2025 · Dec 31, 2025EPS (Diluted)
-1.11CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
70.08MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
70.08MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-77.78MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-101.26MCNYFY2025 · Dec 31, 2025Free Cash Flow
-180.15MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
710.81MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-77.78MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-19.51MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
1.22MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-5.19MCNYFY2025 · Dec 31, 2025Capital Expenditures
-78.89MCNYFY2025 · Dec 31, 2025Purchase of Investments
-2.57BCNYFY2025 · Dec 31, 2025Sale of Investments
2.75BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
102.14MCNYFY2025 · Dec 31, 2025Other Financing Charges
-23.83MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-23.83MCNYFY2025 · Dec 31, 2025Shares Outstanding
69.92MSharesUpdated Oct 24, 2026Float Shares
21.89MSharesUpdated Oct 24, 2026% Held by Insiders
68.11%vs all stocks
% Held by Institutions
6.56%vs all stocks
Total Cash (MRQ)
1.65BCNY248.00M · vs all stocks (USD)
Total Cash per Share (MRQ)
23.80CNYUpdated Oct 24, 2026Total Debt (MRQ)
51.15MCNY7.67M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0256xvs Biotechnology peers
Current Ratio (MRQ)
18.76xvs Biotechnology peers
Book Value per Share (MRQ)
28.75CNYUpdated Oct 24, 2026Total Assets
2.15BCNY322.45M · vs all stocks (USD)
Total Current Assets
1.85BCNYFY2025 · Dec 31, 2025Total Liabilities
116.83MCNYFY2025 · Dec 31, 2025Total Non-current Assets
296.58MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
47.70MCNYFY2025 · Dec 31, 2025Total Current Liabilities
69.12MCNYFY2025 · Dec 31, 2025Cash
711.10MCNYFY2025 · Dec 31, 2025Cash Equivalents
2.31KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
711.10MCNYFY2025 · Dec 31, 2025Accounts Receivable
61.77MCNYFY2025 · Dec 31, 2025Inventory
63.32MCNYFY2025 · Dec 31, 2025Accounts Payable
36.23MCNYFY2025 · Dec 31, 2025Short-term Debt
9.48MCNYFY2025 · Dec 31, 2025Other Current Liabilities
777.57KCNYFY2025 · Dec 31, 2025Long-term Debt
45.60MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
551.14KCNYFY2025 · Dec 31, 2025Common Stock (Book)
70.18MCNYFY2025 · Dec 31, 2025Retained Earnings
-17.77MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.03BCNY304.94M · vs all stocks (USD)
Treasury Stock
11.96MCNYFY2025 · Dec 31, 202552-Week Low
33.20CNYUpdated Oct 24, 202652-Week High
168.03CNYUpdated Oct 24, 202652-Week Change
153.25%vs all stocks
Beta
1.27xvs all stocks
50-Day MA
105.93CNYUpdated Oct 24, 2026200-Day MA
58.69CNYUpdated Oct 24, 2026Avg 10-Day Volume
7.44MSharesUpdated Oct 24, 2026Avg 30-Day Volume
8.28MSharesUpdated Oct 24, 2026Diluted EPS (TTM)
-1.18CNYUpdated Oct 24, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Liquidity Ratios Elevated
It can cover near-term bills from cash alone, not just from inventory.
Reads
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 48.95Revenue Growth YoY: 0.07
High gross margins eroded by operating costsNotable
Gross Margin: 0.67Profit Margin: -0.54
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $22.91M, lower than 95% of all stocks globallySignificant
Revenue (USD): 22,906,286.665Global P5: 36,021,613.518
Companies that share the same coordination system — how they create, deliver, or capture value.
Aurisco Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
BioGaia AB
Tier 1ProductionApproval-Gated PipelineRuleFlow
Jiuzhitang Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
SSY Group Limited
Tier 1ProductionApproval-Gated PipelineRuleFlow
SUDEEPPHRM
Tier 1ProductionApproval-Gated PipelineRuleFlow
Ningbo Menovo Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Sanofi Consumer Healthcare Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Jiangxi Fushine Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Glass House Brands Inc.
Tier 1ProductionApproval-Gated PipelineFlowRule
Avanos Medical Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Pulse Biosciences Inc.
3 interpretationsLiquidity Ratios ElevatedLow-Leverage Liquidity ConfigurationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Apogee Therapeutics Inc.
2 interpretationsLiquidity Ratios ElevatedLow-Leverage Liquidity Configuration
Anterix Inc.
2 interpretationsLiquidity Ratios ElevatedLow-Leverage Liquidity Configuration